The study shows that of those who discontinued their prescribed injectable semaglutide or tirzepatide for obesity: The study, Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice, was published in the journal Obesity
Contains taurine and caffeine
A 2025 systematic review and network meta-analysis of 55 randomized trials (18,876 participants) demonstrated sustained improvements in HbA1c, fasting glucose, body weight, and systolic blood pressure with GLP-1 RAs for up to 104 weeks, although HbA1c and fasting glucose reductions declined slightly (0.36% and 0.47 mmol/L, respectively) after two years [119]
Manufacturers claim these adhesive patches gradually release active ingredients through the skin to support weight loss over time and control appetite
Ignoring these cases would be dishonest, and understanding them is essential for anyone with a migraine history who is considering tirzepatide